Prospektive Therapie-Studie Zur Behandlung Des Desmoplastischen Plattenepithelkarzinoms

University Hospital Tuebingen1 site in 1 country73 target enrollmentJanuary 2016

ConditionsSquamous Cell Carcinoma of the Skin

Overview

Phase: N/A
Intervention: Not specified
Conditions: Squamous Cell Carcinoma of the Skin
Sponsor: University Hospital Tuebingen
Enrollment: 73
Locations: 1
Primary Endpoint: Recurrence free survival of patients with desmoplastic squamous cell carcinoma (SCC) diagnosed with immunohistochemistry .
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Aim of the study is to verify wether it is possible to have a more sensitive diagnostic tool using pancytokeratin immunohistochemistry for desmoplastic squamous cell carcinoma compared to regular H&E staining. The investigators therefore plan to include 73 participants with a confirmed diagnosis of desmoplastic squamous cell carcinoma and do regular follow up.

Registry

clinicaltrials.gov

Start Date

January 2016

End Date

January 2020

Last Updated

10 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

University Hospital Tuebingen

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•desmoplastic squamous cell carcinoma (SCC) of the skin

Exclusion Criteria

•tumor recurrence
•collision tumors
•other skin malignancies
•Rothmund-Thomson-Syndrome
•lacking of the capacity for informed consent

Outcomes

Primary Outcomes

Recurrence free survival of patients with desmoplastic squamous cell carcinoma (SCC) diagnosed with immunohistochemistry .

Time Frame: 4 years

Secondary Outcomes

Presence of perineurial and perivascular tumor invasion according to histological work-up(4 years)
Dimension of the tumor spreading according to histological work-up (measured in mm)(4 years)
Histological pattern of tumour growth (continuous versus discontinuous)(4 years)
Reduction of local recurrence with immunohistochemistry(4 years)